<DOC>
	<DOCNO>NCT00299923</DOCNO>
	<brief_summary>The aim study , compare relapse rate chronic HCV patient genotype 1 3 combination standard dose Peg-Interferon alfa-2a ( PEG-IFN alfa-2a ) , Ribavirin ( RBV ) Amantadine ( AMA ) give 72 week ( group A ) , versus combination , give 48 week ( group B ) patient relapse previous combination therapy conventional pegylated ( PEG ) Interferon alfa Ribavirin . Relapse ist define percentage patient non-detectable HCV-RNA end therapy ( week 48 GT1/ week 24 GT 3 ) become HCV-RNA positive follow-up period 24 week .</brief_summary>
	<brief_title>Study Patients With Chronic HCV ( GT 1 3 ) Who Relapsed Previous ( Peg ) Interferon/ Ribavirin Combination Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Relapsers previous combination therapy ( PEG ) IFN alfa/Ribavirin negative HCVRNA test result end regular treatment course positive HCVRNA test result followup period . Termination ( PEG ) IFN alfa/ribavirin therapy least 3 month prior enrolment Chronic HCV infection genotype 1 3 . Serum HCVRNA quantifiable &gt; 100 IU/mL COBAS AmpliPrep another quantitative HCVRNA PCR test ( report IU ) Compensated liver disease ( ChildPugh A ) Exclusion HCC patient cirrhosis transition cirrhosis . In patient AFP &gt; 50 ng/mL establish assay exclusion HCC do Negative urine blood pregnancy test All fertile male female must use two reliable form effective contraception ( combine ) treatment study drug 6 month post treatment Exclusion Criteria ( screen ) : Hypersensitiveness Interferon , PEGIFN alfa2a , Ribavirin Amantadine ingredient drug Ongoing pregnancy breast feed Male partner woman pregnant woman without effective contraception Signs symptom hepatocellular carcinoma Chronic HCV infection genotype 2 , 4 , 5 6 Therapy systemic antiviral , antineoplastic immunomodulatory treatment &lt; 6 month prior first dose study drug study period . Exception : patient limited ( &lt; 7 day ) course acyclovir valacyclovir herpetic lesion &lt; 1 month prior first administration test drug exclude . Any investigational drug &lt; 6 week prior first dose study drug Positive test antiHAV IgM , HBsAg , antiHBc IgM , antiHIV History evidence medical condition associate chronic liver disease HCV History evidence decompensated liver disease ChildPugh score &gt; 6 . Hb &lt; 12 g/dL ( &lt; 120 g/L ) woman &lt; 13 g/dL ( &lt; 130 g/L ) men screen Any patient increase baseline risk anemia anemia would medically problematic Neutrophil count &lt; 1,500 cells/mm3 and/or platelet count &lt; 90,000 cells/mm3 Serum creatinin concentration &gt; 1.5 mg/dl History severe psychiatric disease , especially depression . History severe seizure disorder stabilize medication History immunologically mediate disease Chronic pulmonary disease associate functional limitation History severe cardiac disease History major organ transplantation except corneatransplantation Evidence severe illness , malignancy , condition would make patient , opinion investigator , unsuitable study Thyroid dysfunction adequately control Evidence severe retinopathy clinically relevant ophthalmological disorder due diabetes mellitus hypertension Evidence active drug abuse within one year study entry except prescribe stable opioid substitution Take Memantine study period Cardiomyopathy myocarditis AVBlock II° III° Preexisting bradycardia &lt; 55 counts/min Known QTinterval ( QTc Bazett &gt; 420 m ) recognize Uwaves congenital QTsyndrome History severe ventricular arrhythmia incl . Torsade de pointes Simultaneous therapy Budipin medicine extend QTinterval like ( e.g.antiarrhythmic drug class IA class III , antipsychotic drug , tri tetracyclic antidepressant , antihistaminics , macrolide , gyrase inhibitor , Azolantimykotics ) Patients obstructive glaucoma Patients excitableness confusion Patients delirium exogenic psychosis anamnesis Prostataadenome Diuretic medication type combination Triamterene/ Hydrochlorothiazide Inability unwillingness provide inform consent abide requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>drug therapy</keyword>
	<keyword>Interferon</keyword>
</DOC>